| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 42 | — | 17.8x | Around median | |
Growth | 31 | 12.0% | 7.1% | Bottom tier | |
Quality | 49 | 4.0% | 4.5% | Around median | |
Safety | 46 | 4.8x | 2.6x | Around median | |
Capital Return | 77 | — | 2.12% | Top tier | |
Momentum | 53 | 35.1% | 2.9% | Around median | |
Sentiment | 94 | 11 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Elanco Animal Health operates in animal health through a portfolio balanced between pet health and farm animals, including dermatology, parasiticide, pain, and vaccine products, alongside solutions for cattle, poultry, and other production animals. The company generates revenue from sales through veterinary clinics, retail, digital channels, and international markets; farm animals account for approximately half of revenue, while the portfolio is geographically distributed between the United States and international markets.
In Q2 of fiscal 2026, revenue reached $1.368 billion, up 10% on a reported basis and 8% organically at constant currency, comprising 6% volume growth and a 2% pricing impact. The pet health business grew 11% organically at constant currency, with 11% growth in the United States and 9% internationally, while the farm animal business grew 5%, with 11% growth in the United States and 2% internationally. Zenrelia and Credelio Quattro led performance, while innovation revenue reached $340 million during the quarter.
Adjusted gross margin reached 58.1% in Q2 of fiscal 2026, up 80 basis points, and adjusted earnings before interest, taxes, depreciation, and amortization reached $288 million, up 21%. Adjusted earnings per share reached $0.34, up 31%, but the available EDGAR data show that net income for the twelve-month period ended in fiscal 2026 remained negative at $242 million and earnings per share were negative by approximately $0.48, highlighting the gap between adjusted operating improvement and cumulative accounting profitability.
The average analyst price target is $28, within a range of $26 to $30, and the average target is close to the upper end of the 52-week range of $27.98, with a consensus Buy rating. No valid positive price-to-earnings multiple is available for comparison because earnings per share for the twelve-month period ended in fiscal 2026 were negative by approximately $0.48. Therefore, the stock's valuation depends more heavily on achieving the adjusted earnings per share outlook of $1.10–$1.16 for fiscal 2026 and converting operating improvement into accounting profits.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Revenue in Q2 of fiscal 2026 reached approximately $1.368 billion, up 10% on a reported basis and 8% organically at constant currency. This growth came from a 6% increase in volume and 2% pricing, with Zenrelia and Credelio Quattro leading product contributions. Both U.S. pet health and U.S. farm animals also grew 11% during the period.
Zenrelia was the largest contributor to Elanco's growth during Q2 of fiscal 2026, and the number of dogs treated with it reached more than 2.5 million. Its reach extended to approximately 18 thousand U.S. clinics, representing more than 60% of the clinic base, with a reorder rate exceeding 80%. Its use as a first-line treatment also exceeded 40% of users, and it became available in 47 countries and achieved the number one position among JAK products in France.
The innovation portfolio generated $340 million in revenue in Q2 of fiscal 2026, with all six major products growing. The company raised its fiscal 2026 innovation revenue target by $50 million to approximately $1.25 billion. Alongside Zenrelia and Credelio Quattro, AdTab grew by more than 30%, and Experior achieved double-digit growth.
Automated analysis for informational purposes only — not investment advice.
The company raised its fiscal 2026 revenue outlook to a range of $5.09–$5.14 billion, with organic constant-currency growth of between 6% and 7%. The adjusted earnings before interest, taxes, depreciation, and amortization range is now $1.01–$1.035 billion, while the adjusted earnings per share range increased to $1.10–$1.16. The company also targets net financial leverage of approximately 3 times by the end of fiscal 2026.
Befrena remains supply-constrained despite reaching approximately 1,400 U.S. clinics, and the company does not expect the constraint to be fully resolved before early 2027. Operating expenses also increased 10% at constant currency in Q2 of fiscal 2026, and Elanco expects an increase of approximately 11% in Q3 of fiscal 2026 as launch spending continues. In addition, there was a net loss of $242 million for the twelve-month period ended in fiscal 2026 and net leverage of 3.1 times.
Adjusted gross margin reached 58.1% in Q2 of fiscal 2026, up 80 basis points from the corresponding period. Adjusted earnings before interest, taxes, depreciation, and amortization increased 21% to $288 million, while adjusted earnings per share rose 31% to $0.34. In contrast, earnings per share according to EDGAR data for the twelve-month period ended in fiscal 2026 remained negative by approximately $0.48, so converting adjusted improvement into accounting net income remains a key point to monitor.
